Identification and characterisation of human apoptosis inducing proteins using cell-based transfection microarrays and expression analysis by Palmer, Ella L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification and characterisation of human apoptosis inducing
proteins using cell-based transfection microarrays and
expression analysis
Citation for published version:
Palmer, EL, Miller, AD & Freeman, TC 2006, 'Identification and characterisation of human apoptosis
inducing proteins using cell-based transfection microarrays and expression analysis' BMC Genomics, vol 7,
pp. 145. DOI: 10.1186/1471-2164-7-145
Digital Object Identifier (DOI):
10.1186/1471-2164-7-145
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BMC Genomics
Publisher Rights Statement:
© 2006 Palmer et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
BioMed Central
Page 1 of 17
(page number not for citation purposes)
BMC Genomics
Open AccessResearch article
Identification and characterisation of human apoptosis inducing 
proteins using cell-based transfection microarrays and expression 
analysis
Ella L Palmer1,3, Andrew D Miller2 and Tom C Freeman*1
Address: 1MRC Rosalind Franklin Centre for Genomics Research (RFCGR), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SB, UK, 
2Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building, Armstrong Road, Imperial College London, London SW7 
2AZ, UK and 3MRC Laboratory for Molecular Cell Biology and Cell Biology Unit, University College London, Gower Street, London WC1E 6BT, UK
Email: Ella L Palmer - ella.palmer@ucl.ac.uk; Andrew D Miller - a.miller@imperial.ac.uk; Tom C Freeman* - drtfreeman@msn.com
* Corresponding author    
Abstract
Background: Cell-based microarrays were first described by Ziauddin and Sabatini in 2001 as a
powerful new approach for performing high throughput screens of gene function. An important
application of cell-based microarrays is in screening for proteins that modulate gene networks. To
this end, cells are grown over the surface of arrays of RNAi or expression reagents. Cells growing
in the immediate vicinity of the arrayed reagents are transfected and the arrays can then be scanned
for cells showing localised changes in function. Here we describe the construction of a large-scale
microarray using expression plasmids containing human genes, its use in screening for genes that
induce apoptosis when over-expressed and the characterisation of a number of these genes by
following the transcriptional response of cell cultures during their induction of apoptosis.
Results: High-density cell-based arrays were successfully fabricated using 1,959 un-tagged open
reading frames (ORFs) taken from the Mammalian Gene Collection (MGC) in mammalian
expression vectors. The arrays were then used to screen for genes inducing apoptosis in Human
Embryonic Kidney (HEK293T) cells. Using this approach, 10 genes were clearly identified and
confirmed to induce apoptosis. Some of these genes have previously been linked to apoptosis,
others not. The mechanism of action of three of the 10 genes were then characterised further by
following the transcriptional events associated with apoptosis induction using expression profiling
microarrays. This data demonstrates a clear pro-apoptotic transcriptional response in cells
undergoing apoptosis and also suggests the use of common apoptotic pathways regardless of the
nature of the over-expressed protein triggering cell death.
Conclusion: This study reports the design and use of the first truly large-scale cell-based
microarrays for over-expression studies. Ten genes were confirmed to induce apoptosis, some of
which were not previously known to possess this activity. Transcriptome analysis on three of the
10 genes demonstrated their use of similar pathways to invoke apoptosis.
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Background
Cell-based microarray technology was first described by
Ziauddin and Sabatini in 2001 [2] for use in performing
high throughput over-expression studies. The technique
entails printing the full-length ORF of genes inserted into
an expression vector onto a glass microscope slide to form
a microarray. The array is treated with transfection reagent
and cells are grown over the top of the array until conflu-
ent. Cells growing in the vicinity of the spots of packaged
genes undergo transfection and the encoded protein is
over-expressed. Arrays can then be examined for altera-
tions in cellular function, as manifested in localised
changes to the cells' biochemistry or morphology. If the
expression vector contains a 'tag', the sub-cellular localisa-
tion of the protein can also be analysed [2,3]. Due to the
techniques' potential for high throughput analyses and
economy of reagents, cell-based microarrays for studies
have now been adopted by a number of groups for a vari-
ety of applications. Cell-based microarray over-expression
studies have been used to discover new members of sig-
nalling pathways [4], to identify new G-protein coupled
receptor (GPCR) targets [5] and to screen single-chain
antibody fragments [6]. Comprehensive reviews on cell-
based microarrays are available elsewhere [7,8].
Whilst in principle cell-based microarrays provide a pow-
erful platform for performing high throughput transfec-
tion screens, to date no studies have reported the use of
large-scale arrays and analyses have tended to focus on the
over-expression of a relatively small number of genes.
One factor that has limited the use of the technology to
date has been the availability of suitable clone sets that
contain tagged full-length ORF's in mammalian expres-
sion vectors, as described in the original paper [2]. Such
clone collections are beginning to become available from
commercial sources, but for most their use is prohibited
by their expense and restrictions on their use. In a previ-
ous study [3], we explored the use of GFP tagged genes in
Gateway expression vectors in the fabrication of cell-based
arrays. Whilst this work demonstrated the utility of using
tagged clones in visualising the sub-cellular localisation of
the transfected protein, it also highlighted certain limita-
tions with this approach. For example, apart from the con-
siderable expense and time involved in sub-cloning genes
into the Gateway cloning system, there is the possibility of
introducing errors into the ORF during the initial PCR of
the cDNA insert. We also demonstrated that tagging a
gene can cause the protein to mis-localise and therefore
disrupt the function of the native protein.
In the current study, we have therefore elected to use
untagged human cDNA clones from the Mammalian
Gene Collection (MGC) [9,10] for the construction of a
cell-based microarray capable of screening a large number
of genes. There is currently a non-redundant set of over
13,000 sequence verified, full-length ORF human clones
in the MGC collection. We have constructed a reverse
transfection array containing plasmid DNA from 1,959 of
these clones, with each clone printed in quadruplicate. A
GFP vector (pEGFP-C1) was also printed to act as a trans-
fection control and to provide a positional address for the
untagged MGC clones.
Apoptosis is a mechanism for regulating cell survival by
which unwanted or damaged cells are induced to undergo
a controlled cell death. During development, apoptosis is
used to remove surplus cells and remodel tissues. After
birth, apoptosis plays additional roles in tissue homeosta-
sis, immune selection and in deleting cells that have
become infected, irreparably damaged, or transformed
[11,12]. The apoptotic cascade may be triggered through
two major pathways. Extracellular signals such as the
tumour necrosis factor (TNF) family of proteins can acti-
vate the receptor-mediated extrinsic pathway. Alterna-
tively, stress signals such as DNA damage or withdrawal of
survival signals may trigger the mitochondrial intrinsic
pathway. Regardless of the mechanism of activation, cells
undergoing apoptosis show characteristic features, which
include chromatin aggregation, nuclear/cytoplasmic con-
densation and partitioning of the cytoplasm and nucleus
into membrane bound-vesicles (apoptotic bodies), which
contain ribosomes, morphologically intact mitochondria
and nuclear material [13,14].
Numerous studies have focused on the identification of
proteins and pathways that control apoptosis. Apart from
the specific interest in understanding how and which pro-
teins regulate the balance between cell survival and cell
death, there is considerable interest in regulating or har-
nessing their activity to modulate disease processes. In the
current study, we have employed cell-based microarray
technology to screen for genes that are pro-apoptotic
when over-expressed. We have then characterised the
activity of a number of the genes identified by following
the transcriptional response of cell cultures undergoing
increased levels of apoptosis due to their over-expression.
In summary, this study has employed a novel approach to
the construction of large-scale cell-based microarrays
which has been used to screen for proteins that induce
apoptosis when over-expressed. Using these arrays we
have been able to identify a number of proteins that
induce apoptosis, some of which are novel in this respect.
Through these studies we have been able to identify com-
mon apoptotic pathways on which the different pro-
apoptotic proteins appear to be acting.
Results
Microarrays were constructed using plasmid DNA from
1,959 human MGC clones in the pCMV-SPORT6 vector.
BMC Genomics 2006, 7:145 http://www.biomedcentral.com/1471-2164/7/145
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All plasmids were printed in quadruplicate within grids
(Figure 1b) except GFP, which was printed in columns to
demarcate the grids and to act as a control for transfection.
Seven genes in the Gateway pcDNA-DEST47 C-terminal
GFP fusion vector for which we have previously character-
ised sub-cellular localisations [7] were also included as
transfection controls. The arrays were incubated with
HEK293T cells for approximately 40 hours, after which
time clear grids of the transfection control pEGFP-C1
could be observed (Figure 1d). Four separate arrays on
two separate occasions were subjected to the Terminal
Deoxynucleotide Transferase dUTP Nick End Label
(TUNEL) assay, which allows the detection of free 3'-OH
termini present in the fragmented DNA of apoptotic cells
(e). Replication of assays was found to be crucial for strin-
gent screening as the ability to obtain a result for an indi-
vidual gene was often compromised by imperfections in
the cell monolayer, either as a result of differences in cell
growth or post-culture treatment of the slides. A protein
was scored as positive for apoptosis if one TUNEL-positive
cell was observed by eye over one or more of the four rep-
licate spots. This was a deliberately low threshold for a
positive readout. The small number of cells over each spot
(30–50), and the fact that apoptotic cells could be cleared
Overview of the design and use of the large-scale cell-based microarray for over-expression studiesFigure 1
Overview of the design and use of the large-scale cell-based microarray for over-expression studies. a. Representative agarose 
gel image of plasmids prepared from 2,976 MGC (IRAT) clones. b. Array was designed such that each clone was printed in 
quadruplicate (yellow and red squares) surrounded by columns of GFP vector (green squares). The position of GFP-tagged 
positive control genes is shown by small white boxes. c. 1,959 plasmids in 0.3% gelatin were printed on to a glass slide in to 
form an array with 9,888 features. The image is of an array scanned directly after printing (Agilent microarray scanner). d. An 
array cultured with HEK293T cells and scanned with a fluorescent imager (GE Healthcare, Typhoon) to show lines of GFP pos-
itive cells. e. Arrays were subjected to a functional assay to detect changes in the cell after over-expression of proteins. The 
image is of TUNEL positive cells, scale bar = 10 μm.
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in the late stages of apoptosis meant that the signal for
even a strong pro-apoptotic gene was potentially weak. 79
of the 1,959 genes (4%) represented on the array were
scored positive in two of the four replicate assays and were
therefore considered to be potentially pro-apoptotic.
The 79 genes were then scrutinised further by examining
their activity when transfected in 6-well plates. The results
from the 6-well experiment indicated that out of the 79
positives from the array, 69 (87.3%) showed no higher
rates of cell death in cultures following transfection than
the controls, with 10 (12.7%) being true positives. The
function, GO descriptions and localisations were
obtained for the 10 pro-apoptotic proteins identified by
this study (Table 1). Some of these are known to be
involved in apoptotic pathways, while others are unchar-
acterised in this respect (see Discussion for a full descrip-
tion of these genes and their potential mechanism of
action).
Gene Ontology (GO) categorisation lists 11 genes on the
array under the apoptosis category. Only one of these
genes (STK3) was observed in the final list of ten positive
genes. Assuming that all 11 of the GO categorised genes
are capable of inducing apoptosis when over-expressed,
the false negative rate of the array based assay can be esti-
mated as 91%. From these numbers the sensitivity could
be estimated as 60%, with an assay specificity measured
by the positive predictive value of 12.1% (see Methods for
details of calculations).
To determine the dynamics of apoptosis induction
brought about by the over-expression of the 10 pro-apop-
totic proteins, all were analysed in plate-based assays,
using both the TUNEL and cleaved-CASP3 assays at 12,
24, 36, 48 and 60 hours following transfection. A mock
transfection and a well-characterised inducer of apoptosis,
staurosporine (STS) were assayed in parallel at each time
point, as negative and positive controls respectively.
Higher levels of apoptosis were observed in cell cultures
over-expressing each of the 10 proteins and the positive
(STS) control relative to the negative control, with levels
of apoptosis rising at later time points (Figure 2).
Three of the 10 proteins, ACO1, STK3 and XBP1 were cho-
sen for further characterisation, by expression profiling of
cell cultures over-expressing the genes. Following transfec-
tion, 12, 24 and 48 hour time points were chosen from
the time-course study in order to cover early, mid and late
gene transcriptional events associated with apoptosis pro-
gression (). RNA samples were labelled and hybridised to
the Affymetrix HG-U133 GeneChip and the data was nor-
malised using both the GeneChip Operating System
(GCOS) and Robust Multivariate Analysis (RMA). All raw
and normalised data has been submitted to ArrayExpress
[1] (Accession Number: E-MEXP-421). The data was of
high quality with the chips showing little variation in the
quality control parameters recorded in the GCOS report
file. Box plots also showed data distributions to be rela-
tively similar across all chips (Additional file 1 Figure
One). Non-supervised clustering of the data using the
conditions tree function within GeneSpring (Agilent
Technologies) suggested that there was little or no treat-
ment or time-specific clustering of the data (Additional
file 2 Figure Two). ACO1, STK3 and XBP1 appeared to be
constitutively expressed within the cells as assessed by the
GCOS software, with these genes being reported as being
present (P) in all the samples at all the time points (data
not shown). XBP1 appeared to have the highest constitu-
tive expression i.e. gave the greatest signal, followed by
ACO1, then STK3. The signal intensities for all three tran-
scripts (ACO1, STK3 and XBP1) increased up to 41, 70
and 12 times, respectively, within cells where the genes
were over-expressed compared with the average expres-
sion level in cell cultures in which the genes had not been
transfected. Mock transfected and STS treated cells
showed no rise in any of the three gene transcripts above
constitutive levels. Despite apparent differences in the
baseline level of expression of the three gene transcripts,
all genes showed similar expression levels (signal) follow-
ing transfection (Figure 3). These three genes exhibited
the most significant fold changes in their expression fol-
lowing transfection relative to any of the genes repre-
sented on the Affymetrix array.
Data normalised using the RMA method, was then used to
prepare a list of differentially expressed genes. ANOVA
analysis was used to compare replicate data from each of
the four test conditions (three over-expressed genes plus
STS treatment) at each time point with the appropriate
negative (mock transfected) control data. Overall, 3,791
gene transcripts were observed to be significantly differen-
tially expressed in at least one of the 12 pair-wise compar-
isons. To refine the list of differentially expressed
transcripts and minimise the false discovery rate, only
transcripts that showed a fold change greater than 1.4 and
appeared in three or more of the 12 individual pair-wise
comparisons were analysed further. This 'Differentials
List' (Additional file 3 Table One) contained 997 tran-
scripts. Based on this list, Venn diagrams were prepared
from the individual comparisons such that the overlap in
genes either differentially under or over-expressed across
time-points could be assessed (Figure 4). Overall, there
was considerable overlap in the genes found to be differ-
entially expressed across time-points, but there also
appeared to be many that were specific to individual time
points. Of all the transcripts found to be differentially
expressed following transfection, an average of 78.2%
across all time points and transfections were observed to
decrease in expression. However, the overall number of
BMC Genomics 2006, 7:145 http://www.biomedcentral.com/1471-2164/7/145
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Table 1: Summary of the 10 genes found in these studies to induce apoptosis when over-expressed. Function, sub-cellular localisations 
and GO categories of the genes are given. Yellow highlights GO apoptotic activity.
Gene name Function Proposed apoptotic 
hypothesis
Localisation 
(Swiss-Prot)
GO categories
C22ORF23 Not known None Not known Not known
XBP1 XBP1 binds to the X box of the HLA-DR-alpha 
promoter (MHC human class II gene) [20] and 
responds to accumulation of unfolded proteins 
in the ER [21].
XBP1 increases ER membrane 
production, this change in intra-
cellular balance may trigger 
apopotosis.
Nuclear - Immune response
- Nucleus
- Regulation of 
transcription
- Transcription factor 
activity
CSTB The main role of cathepsins is the degradation 
of protein. Maintenance of appropriate 
equilibrium between free cysteine proteases 
and their complexes with inhibitors is crucial 
for proper functioning of all living systems [23]. 
Mutations in CSTB result in myoclonus epilepsy 
[35].
If cathepsins are highly inhibited 
by CSTB, this could prevent 
degradation of peptides and 
proteins, which could stimulate an 
apoptotic pathway.
Cytoplasmic 
and nuclear.
- Cysteine protease 
inhibitor
- Nucleus
MGC5439 Not known None Not known Not known
STK3 STK3 and 4 are involved in Fas mediated 
apoptosis and are cleaved/activated by CASP3. 
When stably expressed in HeLa cells, STK3 and 
4 highly sensitise the cell to death receptor 
mediated apoptosis by accelerating CASP3 
activation [19].
These findings suggest that STK3 
and STK4 play a role in apoptosis 
both upstream and downstream 
of caspase activation [16].
Cytoplasmic 
(By similarity)
- Protein kinase CK2 
activity
- Serine/threonine kinase 
activity
- cAMP-dependent kinase 
activity
- Cytoplasm
- Smino acid 
phosphorylation
- Tyrosine kinase activity
- Transferase activity
- Apoptosis
- ATP binding
- Signal transduction
ACO1 Transferrin receptor (Tfr) is a membrane 
receptor that transports iron into the cell via 
endocytosis. Free iron is toxic to cells, but not 
if bound to ferritin. ACO1 (IREBP – IRE binding 
protein) [25] represses ferritin translation and 
increases Tfr translation [24].
Over-expression of ACO-1 will 
cause increased Tfr and excess 
iron within the cell. Ferritin 
translation is repressed by ACO1 
so the excess free iron will be 
unbound. Excess intracellular iron 
induces apoptosis in cells.
Cytoplasmic - Lyase activity
- Tricarboxylic acid cycle
- Aconitate hydratase 
activity
- Cytoplasm
- Negative regulation of 
translation
- Metabolism
- RNA binding
MLLT11 Involved in acute leukemias by a chromosomal 
translocation. MMLT11 could possibly be a 
cytokine [36].
None Not known - Cell growth and/or 
maintenance
CCBP2 CCBP2 is a promiscuous receptor [37], binds 
to SCYA2/MCP-1, SCY3/MIP-1-ALPHA, 
SCYA5/RANTES AND SCYA7/MCP-3. CCBP2 
is expressed in the lymphatic endothelium, a 
subset of vascular tumors [37] and melanoma 
cells [38].
None Integral 
membrane 
protein
- Immune response
- Integral to plasma 
membrane
- Development
- G-protein coupled 
receptor
- Chemotaxis
- C-C chemokine receptor 
activity
- Rhodopsin-like receptor 
activity
LOC134285 No information -Receptor activity
BMC Genomics 2006, 7:145 http://www.biomedcentral.com/1471-2164/7/145
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gene transcripts that increased and decreased in expres-
sion was similar following treatment with STS. There were
more transcripts in the XBP1 differentials lists than with
other treatments and there were no obvious time point-
specific trends in the number of gene transcripts increas-
ing or decreasing in expression across the conditions.
Supervised clustering of the 997 transcripts present in
three or more of the individual comparisons was used to
assess the behaviour of these genes across the four experi-
mental conditions. This revealed a surprising uniformity
in the behaviour of genes across different time points and
treatments (Figure 5). Whilst individual genes showed
some variation across the data set, genes that were up or
down regulated in one comparison tended to show the
same behaviour across all comparisons, although this
change didn't always reach the level of statistical signifi-
cance.
In an effort to associate the genes found to be differen-
tially expressed in this experiment with apoptosis, we uti-
lised the University of Michigan list of apoptosis
regulators [15]. This resource was used as it listed a large
number of genes that according to the literature are poten-
tially involved in apoptotic pathways. Of the 1,099 apop-
tosis regulators listed on this site, 130 were present in the
differentials list generated by this experiment. This 'Apop-
tosis Differentials List' was therefore a list of differentially
expressed genes that have been previously associated with
apoptosis (Additional file 4 Table Two). The Apoptosis
Differentials List contained genes that belonged to the
same family and there were also genes that had known
EXOC7 
(KIAA1067
)
EXOC7 is 1 of 8 subunits of the exocyst which 
transports material within membrane bound 
vesicles inside the cell to the surface. The 
intracellular vesicles fuse with the plasma 
membrane and contents are released to the 
exterior [26].
Over-expression of EXOC7 may 
cause excessive removal of 
internal cell contents and cause 
apoptosis to occur.
Cytosolic - Intracellular protein 
transport
- Exocytosis
- Exocyst
- Protein transporter 
activity
Table 1: Summary of the 10 genes found in these studies to induce apoptosis when over-expressed. Function, sub-cellular localisations 
and GO categories of the genes are given. Yellow highlights GO apoptotic activity. (Continued)
Percentage of apoptotic cells after over-expression of the 10 pro-apototic genesFigure 2
Percentage of apoptotic cells after over-expression of the 10 pro-apototic genes. STS treatment and mock transfection in 6 
well plate CASP3 assays.
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ACO1, STK3 and XBP1 expression following transfection in six-well platesFigure 3
ACO1, STK3 and XBP1 expression following transfection in six-well plates. ACO1, STK3 and XBP1 probe set RMA normalised 
signal intensities were plotted over the time course for each combined sample. Results for replicate samples were averaged, 
error bars indicate the individual replicate measurements.
BMC Genomics 2006, 7:145 http://www.biomedcentral.com/1471-2164/7/145
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Venn diagrams prepared with the list of 997 differentially expressed transcriptsFigure 4
Venn diagrams prepared with the list of 997 differentially expressed transcripts. I↑ and ↓D, number of genes increased or 
decreased in expression respectively, compared to the mock transfection control at that time point. Venn diagrams, 12 hours 
(red), 24 hours (blue), 48 hours (white). Boxes; No. genes – gene number increasing or decreasing at that time point, % I+D – 
percentage of genes increasing or decreasing at that time point.
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Gene tree prepared with the list of 997 differentially expressed transcriptsFigure 5
Gene tree prepared with the list of 997 differentially expressed transcripts. The tree was generated using the Spearman corre-
lation algorithm within GeneSpring. Expression is shown in fold change compared to the appropriate mock transfection con-
trol. Red – genes increased in expression; Green – genes decreased in expression; Black – unchanged.
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interaction partners (see Discussion and Additional file 4
Table Three for more detail).
In an effort to piece this information together, proteins
within the Apoptosis Differentials List were marked red if
they are thought to be pro-apoptotic and green if they
appeared to increase the likelihood of cell survival based
on the literature (Additional file 4 Table Two). If genes
could be categorised in this way, we endeavoured to place
them on a simplified Kyoto Encyclopedia of Genes and
Genomes (KEGG) apoptosis pathway to give an indica-
tion of their likely site of activity within the apoptotic
pathway.
Figure 6 attempts to summarise this information by show-
ing genes/pathways that appear to be central to apoptosis
induction in the current study (see Additional file 5 Fig-
ures Three to Seven for separate figures of the simplified
KEGG pathway for each time point/transfected gene).
Discussion
The aim of this study was to adopt a functional genomics
approach to screen for human genes that induce apoptosis
when over-expressed. In order to do this, our strategy
required the construction of a microarray of a large
number of human genes in mammalian expression vec-
tors. In a previous study, GFP-tagged genes in Gateway
expression vectors were used to examine the sub-cellular
localisation of proteins over-expressed by reverse transfec-
tion [3]. In common with other studies, we found that
gene-tagging can disrupt the normal sub-cellular localisa-
tion and therefore presumably the function of the protein.
Summary of the effects of gene over-expression on the mRNA levels for genes associated with apoptotic pathwaysFigure 6
Summary of the effects of gene over-expression on the mRNA levels for genes associated with apoptotic pathways. Central 
pathway has been adapted from the KEGG apoptotic pathways (light blue) and BD Biosciences apoptotic pathway (light 
orange). A gene is shown on the pathway if present in at least one of the time points in at least three of the 4 individual treat-
ments. Arrows within the gene mRNA boxes indicate genes with increased or decreased expression. Genes coloured red 
potentially increase apoptosis, genes coloured green potentially decrease apoptosis according to the literature (see Additional 
file 4 Table Two and Three and Additional file 5 Figures Three to Seven for Apoptosis Differentials List and more comprehen-
sive pathways).
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In addition, sub-cloning of the gene inserts has the poten-
tial to introduce errors in the ORF during vector construc-
tion and inserting large numbers of genes into Gateway
constructs is both costly and time consuming. Therefore,
for the present study we decided to adopt a new approach
to the construction of a high-content microarray of
human genes by direct use of the readily available full-
length MGC clones [9,10]. This strategy was possible as
many of the MGC clones were already in the pCMV-
SPORT6 vector, which contains a CMV promoter to drive
expression of the ORF in mammalian cells. Plasmid prep-
arations were attempted for 2,976 MGC clones but we
found that many did not yield enough/any product,
despite repeated attempts. However, more than 2 μg plas-
mid DNA was recovered from 1,959 clones. In order to
maximise the likelihood of observing the effects of over-
expression on the cells covering arrays without compro-
mising the array content, each of the 1,959 purified MGC
clones was printed in quadruplicate onto a glass slide to
form the array. After inclusion of control features, the
array possessed 9,888 features in total. As such, this repre-
sents the largest over-expression cell-based reverse trans-
fection microarray published to date.
Following growth of HEK293T cells over the array, the
TUNEL assay was used to detect genes which had induced
cell death when over-expressed. The assay was repeated on
four separate arrays. When proteins only positive in two
or more of the four assays were taken into account, 79 of
the 1,959 genes (4%) appeared to be potentially inducing
cell death. For verification, these 79 genes were then trans-
fected in 6-well plates. The results from the 6-well plate
assay indicated that out of the 79 positives from the array,
10 (12.7%) were true positives (Table 1). This would indi-
cate that the arrays gave a fairly high false positive rate.
Calculation of the false negative rate presents more of a
challenge. However, in an attempt to evaluate this we
determined the number of genes on the array that have
been linked with apoptosis by Gene Ontology (GO) cate-
gorisation. Eleven genes on the array were listed under the
apoptosis category, but only one of these genes (STK3)
was observed in the final list of 10 positive genes. Assum-
ing that all of these genes are capable of inducing apopto-
sis when over-expressed, the false negative rate of the array
based assay was estimated as 91%. Whether all 11 genes
are truly capable of inducing apoptosis if over-expressed
and whether they would do so in all cell types is uncertain.
The high false positive and estimated false negative rates
of this assay are attributable to a number of factors. In
order to maintain the positional address of the positive
signals relative to the marker gene (GFP) transfections
during manual inspection of the arrays, it was necessary to
view the array at a relatively low magnification (×10
objective). At this resolution the relatively weak signal
produced by TUNEL assay may have been overlooked or
background signal attributed incorrectly. Employing auto-
mated high resolution scanning and image analysis tools
would not only make scoring of cell-based arrays a lot eas-
ier, but would also improve the accuracy of scoring. The
necessity for spot recognition software and the storage
and analysis of the images present a considerable chal-
lenge. These issues are currently being explored and a
microscope-based screening platform is being developed
with automated sample preparation, image acquisition
and data analysis [16,17]. Improved tools for automated
image analysis of cell-based arrays are also being devel-
oped elsewhere [18].
Of the 10 proteins found by this study to induce apoptosis
when over-expressed a number have been linked previ-
ously with apoptosis, others have not. STK3 is known to
be involved in Fas-mediated apoptosis and is cleaved/acti-
vated by CASP3 [19]. In addition, it is possible to hypoth-
esise mechanisms of action of four of the other proteins
identified. XBP1 binds to the X-box of the HLA-DR-alpha
promoter (MHC human class II gene) [20] and responds
to accumulation of unfolded proteins in the ER [21]. It is
possible that this change may trigger apoptosis, although
this has not been demonstrated previously. There is other
evidence that XBP1 may be linked to apoptosis. In an
expression profiling study of murine mammary epithelial
cells expressing conditionally active STAT3 (which pro-
vides an essential death signal for mammary epithelial
cells following weaning), XBP1 was highly up-regulated
following STAT3 activation [22]. CSTB maintains appro-
priate equilibrium between free cysteine proteases and
their complexes [23]. Cathepsins can be inhibited by
CSTB and therefore this could prevent degradation of pep-
tides and proteins, which in turn could possibly act as a
pro-apoptotic stimulus. ACO1 represses ferritin and
increases TFR translation [24], and its over-expression is
therefore likely to cause a build up of free-iron within the
cell. Previous studies have shown that increased levels of
intracellular free-iron can induce apoptosis [25]. EXOC7
is a component of the exocyst complex involved in the
docking of exocystic vesicles with fusion sites on the
plasma membrane [26] and potentially excessive removal
of internal cell contents may cause apoptosis to occur.
MLLT11 and CCBP2 are both found in tumours, but no
other information is available to allow speculation on a
possible mode of action for their induction of apoptosis.
The same is true of the relatively uncharacterised genes
C22ORF23, MGC5439 and LOC134285.
From even the limited number of 'pro-apoptotic' genes
identified by this study, it would appear that they could be
further classified into two categories; those that are 'true'
apoptotic modulators, the proteins they encode being
directly involved with the cell's apoptotic/survival
machinery; and those that act indirectly, their over-expres-
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sion leading to cytotoxic changes within the cell which
then triggers a pro-apoptotic response. It is inevitable that
screens such as this will expose genes in both categories
and further work is necessary to determine their exact
mode of action. Whilst 'true' apoptotic modulators might
be considered more interesting in the pursuit of improved
understanding of the apoptotic cascade, genes that give
rise to apoptosis by indirect mechanisms may still have
interest as novel therapeutic agents, for example in cancer
gene therapy.
In an attempt to ascertain the timing and strength of
apoptosis, a time course transfection study using
HEK293T cells was undertaken on all 10 genes, a positive
control STS and a mock transfected negative control at 12,
24, 36, 48 and 60 hours following transfection. Stau-
rosporine (STS) was used as the positive control as it is an
apoptotic effector classically linked to caspase activation
[27]. As the TUNEL assay has been shown to potentially
detect necrotic death in addition to apoptotic death [28],
a cleaved CASP3 assay was performed on the cultures in
addition to the TUNEL assay. STS and all 10 genes identi-
fied by the reverse transfection screen led to cultures in 6-
well plates exhibiting between 40–70% TUNEL and
cleaved CASP3 positive cells after 60 hours compared with
only 3–4% in the mock transfection cultures.
Apoptosis has been studied extensively and core pathways
and events are generally well established. The regulation
of apoptotic cell death is a complex interplay between
proteins that promote cell survival and those that pro-
mote cell death. It is widely thought that the processes
that control the balance between the life and death of a
cell are regulated exclusively at the post-transcriptional
level. As a result few observations have been made of the
transcriptome during this process, although those that
have [29] suggested that this would be a useful approach
to further characterise the action of these genes.
STK3, ACO1 and XBP1 were selected over the other seven
genes for expression profiling studies (Figure 2) as the
proteins they encode had either been shown in previous
studies to induce or be connected to apoptosis (STK3 and
XBP1) or a clear apoptotic hypothesis could be postulated
(ACO1). For the expression profiling study, samples were
taken at 12, 24 and 48 hours following transfection to
observe the early, mid and late transcriptional events asso-
ciated with apoptosis. ACO1, STK3 and XBP1 were all
found to be constitutively expressed within the cells but at
different levels. It was interesting to note that despite dif-
ferences in constitutive expression, all genes appeared to
reach a similar level of up-regulation following transfec-
tion and that the changes in expression observed for these
transcripts were the largest of all the transcripts repre-
sented on the expression profiling array.
It was envisaged that expression profiling experiments
might reveal a transcriptional response in these cultures
that would provide clues as to the mechanism by which
the over-expression of these genes induces apoptosis.
Overall, analysis of the microarray expression data indi-
cated that the changes observed at all time points and
across all conditions were relatively subtle. There was no
strong tendency for the data to cluster according to treat-
ment or time-point (Additional file 2 Figure Two). The
lists of differentially expressed transcripts of genes pre-
pared by comparing each time point with its respective
mock transfection control, showed many genes to be sig-
nificantly changing their expression, but on the whole
these changes were relatively small i.e. the majority of
changes were less than 2-fold in magnitude. For each
transfection experiment, many more transcripts were
down-regulated in expression than up-regulated during
apoptosis progression. A similar observation was also
reported in a previous study of the transcriptional events
associated with apoptosis following removal of cell sur-
vival factors from cultures of HUVEC cells [29]. However,
with STS treatment the number of gene transcripts that
were significantly down-regulated and up-regulated in
expression overall was similar. What this indicates with
respect to the fundamental mode of action for STS in
apoptosis induction as opposed to the gene over-expres-
sion is uncertain. The number of transcripts identified as
significantly changing with each treatment and at each
time point varied considerably. In order to compare the
condition or time-specific changes in transcript expres-
sion between the genes, a gene tree was plotted of the 997
transcripts that had changed in expression more than 1.4-
fold and that were present in 3 or more of the 12 pair-wise
treatment comparisons (Figure 5). There was a surprising
degree of uniformity in behaviour of these genes across all
conditions and time points. Genes that were up- or down-
regulated in one comparison tended to show the same
behaviour across all comparisons, although this change
did not always reach the level of statistical significance.
Indeed, we were unable to find any convincing condition-
specific changes in transcriptome activity that might give
clues as to the mechanism by which functionally distinct
genes induce apoptosis when over-expressed. Whether
this is because the events leading to the initiation of a pro-
apoptotic response occurred post-transcriptionally or that
the changes are too subtle to be recognised is unclear.
Rather, these findings strongly indicate that the majority
of the changes we observed were associated with a univer-
sal pattern of gene regulation during apoptosis, regardless
of the initiating trigger.
In order to further explore the apoptotic signatures in this
data, the University of Michigan list of apoptosis regula-
tors [15] was used to identify other potentially interesting
apoptosis-associated genes in the list of differentials. 130
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genes were shared between this list and the list of genes
found here to be differentially expressed. Many gene fam-
ily members and known interactors that have been previ-
ously associated with either the pro-apoptotic or cell
survival machinery were present within this new list of
130 apoptosis-associated genes. (The full list of these
genes and an in depth discussion of their potential role in
apoptosis induction or cell survival is available in the
Additional file 4 Tables Two and Three). A literature
search was performed on the 130 genes in the list to ascer-
tain their function. Some apoptosis associated genes e.g.
NR4A1, EGR1 SLIT2, CASP9, ADM, SMAD7, JUN and
TIMP1 significantly changed in their expression in every
transfection/treatment compared to the negative control;
others were only observed to change under certain condi-
tions. In order to provide a simplified view of this data,
these genes were mapped onto a modified version of the
KEGG apoptosis pathway if they were present in at least
three of the four experimental conditions. Their action in
either increasing or decreasing the likelihood of apoptosis
and their directional change in expression is indicated
(Figure 6, also see Additional file 5 Figures Three to Seven
for apoptosis pathways and further discussion for each of
the over-expressed gene and STS treatments). Overall, this
approach supported the hypothesis that the transfected
genes and STS were ultimately acting through similar
pathways to induce cell death. In each case, numerous
genes were observed to change which were associated
with the MAPK8(JNK)/CASP3 pathway and in addition
there were clear indications of suppression of the cell sur-
vival pathways. Whilst the KEGG pathway was helpful in
visualising the apoptotic pathways, many of the genes on
the University of Michigan list of apoptosis regulators [15]
had to be added onto the pathway. In addition, there are
most likely other genes in the lists of differentials that will
be influencing the progression of apoptosis, but have not
yet been recognised as being involved with the regulation
of cell death.
Overall, the expression profiling studies have provided
valuable insights into the transcription changes associated
with apoptosis, as the transcriptional changes associated
with programmed cell death have not been studied exten-
sively. This current study supports the notion that there
are discrete changes in the mRNA abundance of certain
genes during apoptosis [29]. As many of these transcripts
encode proteins that are known regulators of cell survival
and death, it would seem likely that transcriptional regu-
lation of these mediators contributes to a cell's final deci-
sion to undergo a programmed cell death.
Conclusion
This study reports the design and use of the first truly
large-scale cell-based microarray for studies using the
approach described first by Ziauddin and Sabatini [2]. It
has demonstrated the potential as well as the current lim-
itations of this technology to screen large numbers of
genes for those that induce a functional change in cellular
physiology when over-expressed. We have identified 10
genes by this methodology that can induce apoptosis
when transfected into HEK293 cells, some of which have
been previously associated with apoptosis and others
which have not. In order to examine the functional activ-
ity of these genes, a time course expression profiling
experiment was set up to follow the transcriptional
changes associated with apoptosis induction for three of
the genes. This revealed that apoptosis induction is asso-
ciated with discrete changes in a cell's transcriptome and
that many of these changes seem identical regardless of
mechanism by which apoptosis has been induced. Fur-
thermore, many of the genes observed to change in their
expression level during cell death have previously been
associated with apoptosis and in this study strongly indi-
cate the activation of the MAPK8(JNK)/CASP3 and BCL2
pathways.
Methods
Clone purification
MGC clones [8,9] in IRAT plates 1–21 and 36–45 were
purchased from MRC geneservice [30]. Replicate working
plates were prepared by adding 1 μl of IRAT plate clones
to 2X TY media containing 8% glycerol (Sigma, Gilling-
ham, Dorset, UK) and 50 μg/ml ampicillin (Sigma),
grown at 37°C overnight and stored at -20°C. Clones
from each IRAT plate were grown and purified four times.
Clones were grown by adding 10 μl of the working plate
clones to 1 ml 2X TY media containing 50 μg/ml ampicil-
lin and grown for 26 h at 37°C in a shaking incubator at
320 rpm. Clones were purified as described in the
MultiScreen96 PLASMID plate kit protocol (Millipore,
Watford, UK).
pEGFP-C1 (Clontech, Cowley, Oxford, UK) was propa-
gated as described in the DH5α E. coli kit protocol, (Invit-
rogen, Paisley, UK), glycerol stocks were prepared from
850 μl of the culture and 150 μl of glycerol and stored at
-70°C. 10 μl of pEGFP-C1 glycerol stock was added to 5
ml 2X TY media with 100 μg/ml kanamycin (Sigma) and
10 μl glycerol stocks of CXADR, MARKL1, TGIF, CDK9,
NFIB, IL17BR, TNFRSF10B Gateway C-terminal GFP des-
tination vector pcDNA-DEST47 (Invitrogen) prepared as
described previously [7] were added to 5 ml 2X TY media
with 100 μg/ml ampicillin and grown in a shaking incu-
bator at 37°C for 8 h. The pEGFP-C1 was transferred to
flasks containing 100 ml 2X TY media with 100 μg/ml
kanamycin and pcDNA-DEST47 and pCMV-SPORT6
clones were transferred to flasks containing 100 ml 2X TY
media with 100 μg/ml ampicillin and grown at 37°C for
16 h in a shaking incubator, the clones were purified as
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described in the plasmid midiprep kit protocol (Qiagen,
Crawley, West Sussex, UK).
IRAT clones for the 10 apoptotic inducing genes; XBP1,
CSTB, MGC5439, STK3, C22ORF23, ACO1, MLLT11,
CCBP2, LOC134285 and EXOC7 were streaked out on 2X
TY agar plates containing 100 μg/ml ampicillin and incu-
bated overnight at 37°C. A single colony was picked from
each. XBP1, CSTB, MGC5439, STK3 and C22ORF23 were
grown up and purified as the pcDNA-DEST47 clones
described above. ACO1, MLLT11, CCBP2, LOC134285
and EXOC7 were grown up in 5 ml 2X TY media with 100
μg/ml ampicillin at 37°C for 12–16 h with vigorous shak-
ing and plasmids were prepared as described in the Wiz-
ard miniprep kit protocol (Promega, Southampton, UK).
The 96-well Picogreen dsDNA Quantitation Kit (Molecu-
lar probes, Paisley, UK) and the Cytofluor 4000 with
Cytofluor software (Applied Biosystems, Warrington, UK)
and Cytocalc (Applied Biosystems) were used to quantify
96-well miniprep purified IRAT clones. Concentrations
were adjusted to a 200 ng/ml control. A Jenway Spectro-
photometer (Genova Lifescience, UK) was used to meas-
ure all other clone purifications. All samples were
electrophoresed on 1% ethidium bromide agarose gels.
Re-array plates
Plasmid DNA from IRAT plates 1–21 and 36–45 with con-
centrations over 2 μg were re-arrayed into 21 fresh 96-well
flat bottomed plates. The DNA was dried via a heated vac-
uum centrifuge (Eppendorf, Westbury, US), H2O was
added back to a 0.5 μg/μl concentration and the plates
were stored at -20°C.
Printing of cell-based transfection arrays
1 μg IRAT plasmids, pEGFP-C1 vector (Clontech) and
TNFRSF10B, IL17BR, NFIB, CDKN1B, NFIL3 and PTPN11
in the pcDNA-DEST47 vector (Invitrogen) were made up
to 30 μl with 0.3% gelatin (Sigma) and transferred into
384-well plates. Clones were printed onto poly-lysine
slides (Sigma) using a Biorobotics MicroGrid II Microar-
rayer (Biorobotics, Cambridge, UK) with a 48 pin head
(Quill pins 2500, Biorobotics). The microarrayer was pro-
grammed to print 16 single pre-spots, 12 spots with a 25
ms dwell with two 7 sec, 60°C wash and dries between
picking up clones. To determine if the DNA had printed
correctly, arrays were scanned with Cy3 and Cy5 lasers on
a DNA microarrayer scanner (Agilent Technologies, West
Lothian, UK), the resultant .tif files were split using Tiff
splitter A5.1.1.1 (Agilent Technologies) and viewed with
the software program Image Analysis A.5.1.1 (Agilent
Technologies). Each spot was ~140 μm in diameter.
Arrays were stored desiccated at 4°C.
Transfection of arrays
16 μl Enhancer (Effectene transfection reagent kit, Qia-
gen) and 150 μl EC buffer (Qiagen) per array were incu-
bated at RT for 5 min, 25 μl Effectene (Qiagen) was added
and the total volume pipetted onto the array. Parafilm
(Teklab, Durham, UK) was cut to the size of the slide was
lowered onto the array and the transfection reagent incu-
bated on the array at RT for 20 min. The parafilm and
transfection reagent was removed, and arrays were placed
in a 10 × 10 cm square dish (BD biosciences, Cowley,
Oxford, UK). Human embryonic kidney (HEK293T) cells
were grown and maintained in 500 ml DMEM with 0.11
g/l NA PYR with pyroxidine containing 50 ml FCS, 100 U/
ml penicillin, 100 μg/ml streptomycin (Invitrogen) at
37°C and 5% CO2. 1 × 107 HEK293T cells were incubated
at 37°C, 5% CO2 for 24 h before reverse transfection, after
24 h, 1 × 107 cells in a total of 20 ml culture medium were
carefully poured into the 10 × 10 cm dish and incubated
at 37°C, 5% CO2 for 40 h.
6-well plate transfections
22 mm coverslips (VWR) were coated with 0.01% poly-l-
lysine solution (Sigma) and placed in 6-well plates. The
79 positive clones from the reverse transfection screen
were added in Effectene transfection reagent (Qiagen)
according to manufacturer's recommendations to 2 × 105
HEK293T cells and incubated for 40 h. Cover slips were
removed and the TUNEL assay performed (see below).
For the time course, all cell cultures were set up at the
same time and transfections or STS treatment were per-
formed at different points during culture, so all cell cul-
tures were at the same growth phase when harvested. Cells
were seeded into 5 wells per treatment/time point, then
the 10 verified positive apoptotic IRAT clones, a negative
control (transfection reagent only) and a positive control
(final concentration 1 μm staurosporine (STS)) were
added to the cells for 12, 24, 36, 48 and 60 h, then the
TUNEL and cleaved CASP3 assay applied (see below).
Cells were removed and frozen from three wells per treat-
ment/condition for the time course and stored at -70°C
for subsequent Affymetrix microarray sample preparation.
TUNEL and cleaved CASP3 assays
For the TUNEL assay, cells were fixed with 1% paraformal-
dehyde (38% paraformaldehyde (VWR, Dorset, UK),
diluted with PBS) for 10 min and the protocol followed as
described in the Apoptag Apoptosis Detection System kit
protocol (Flowgen, Nottingham, UK). 200 μl TdT
enzyme/reaction buffer, anti-digoxigenin antibody/block-
ing solution and blocking solution were added per cell-
based microarray and 50 μl per 6-well plate coverslip.
For the cleaved CASP3 assay, cells were fixed with 3.8%
paraformaldehyde for 20 min and the protocol followed
as described for the cleaved caspase-3 (Asp175) antibody
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with fluorescein conjugate (Cell Signalling Technology,
Beverly, Massachusetts, USA). 50 μl of diluted cleaved
CASP3 antibody was added per 6-well plate coverslip, a
circle of parafilm (Teklab, Durham, UK) was applied to
ensure even coverage of antibody and incubated shielded
from light at 4°C for 8 h.
Cell visualisation and counting positive cell fluorescence
A drop of mounting medium containing DAPI stain (Vec-
tor, Peterborough, UK) was applied to a glass slide cover-
slip (Agilent) for the cell-based microarrays or to the 6-
well plate coverslip and lowered onto the cell-based
microarray or a standard glass microscope slide for the 6-
well plate coverslips (Amersham Biosciences, Bucking-
hamshire, UK). Fluorescence was primarily visualised
using a Typhoon scanner (Amersham Biosciences) with a
resolution of 50 μm to determine if transfection had
occurred. This level of resolution was not high enough to
analyse the transfection events on the arrays, therefore an
Eclipse E800 microscope (Nikon, Kingston Upon
Thames, UK) with a confocal attachment (BioRad, Hemel
Hempstead, UK) was used to analyse the arrays at ×10
magnification. At this magnification, the GFP positive
controls could be used as a positional tool. Positives were
recorded as a quadruplicate clone patch with one or more
fluorescent cells. Each microarray was scored twice and
the genes were ranked in Excel according to the number of
positives. For the TUNEL and cleaved CASP3 6-well plate
assays, cells were scored as positive if clear fluorescent
apoptotic bodies were observed in or near the cells. The
number of cells in patches of cleared cells were estimated
and included in the total percentage of apoptotic cells.
Slides were stored at 4°C.
Statistical analysis of transfection assays
The distribution of probabilities was calculated based on
constant probability.
The number of measurable array positions for each plas-
mid was divided by the probability distribution and the
number of positive's expected by chance for each plasmid
was calculated. This number was compared to the actual
number observed on the arrays.
To calculate the sensitivity of the arrays, the equation True
Positive (TP)/(True Positive (TP) + False Negative (FN))
was used. TP was calculated as the number of positives in
the 6-well assay follow up experiments. FN was calculated
as the number of known tyrosine apoptosis inducing
genes (determined using Gene Ontology) on the reverse
transfection array that should have been positive, but
were not found to be positive.
The equation True Positive TP/True Positive (TP)+False
Positive (FP) was used to calculate the Positive Predictive
Value of the arrays. False Positive (FP) was calculated as
the number of genes that were found to be positive in half
of more of the reverse transfection arrays, but in the fol-
low up 6-well plate assay were not found to be positive.
Sample preparation for Affymetrix GeneChip microarrays
RNA was extracted as described in the RNeasy mini kit
protocol (Qiagen) from the three frozen time course sam-
ples for STK3, ACO1, XBP1 transfections and the positive
and negative control. cDNA was prepared using the T7-
(dT)24 primer (5'ggccagtgaattgtaatacgactcatagggaggcgg-
(dT)243') (SigmaGenosys) as described in the SuperScript
DoubleStranded cDNA synthesis kit (Invitrogen) from the
two samples per condition with the highest RNA yields.
cDNA was purified as described in the 1.5 ml Heavy Phase
lock Gel (PLG) tubes protocol (Fisher Scientific, Lough-
borough, UK). Biotin labelled cRNA was prepared by in
vitro transcription (IVT) from the cDNA as described in
the Bioarray High Yield RNA transcript labelling kit
(Enzo, New York, USA) and cleaned up as described in the
RNeasy Mini kit (Qiagen). The cRNA was fragmented as
described in the GeneChip Expression Analysis Affymetrix
Manual [31]. RNA, cRNA and fragmented cRNA was
checked on the Agilent 2100 Bioanalyzer using the RNA
6000 assay (Agilent, West Lothian, UK) with universal
RNA as a control (Stratagene, Cambridge, UK) and RNA
6000 ladder (Ambion, Huntingdon, UK). cDNA and RNA
was quantified with the Nanodrop (Labtech International
Ltd, East Sussex, UK). The hybridisation cocktail was pre-
pared and the GeneChips hybridised and washed as the
GeneChip eukaryotic control kit (Affymetrix) and the
GeneChip Expression Analysis Affymetrix Manual [31].
The GeneChips were scanned using the Scanner 3000
(Affymetrix) and the GeneChip Operating System
(GCOS) (Affymetrix).
Data analysis
The .cel data was normalised using GCOS (Affymetrix)
and Robust Multichip Analysis (RMA), which is available
as a programme, called 'affy' from Bioconductor [32]. The
.txt GCOS and RMA normalised data were loaded into
GeneSpring 7 (Silicon Genetics, Redwood City, Califor-
nia). A list of genes differentially expressed between each
condition time point and the negative control sample at
the relevant time point was prepared in 3 stages: 1. the
GCOS normalised data was filtered to remove any gene
not flagged as being present (P) in both replicate samples
in at least one condition/time point. 2. The GCOS Present
lists (1.) were used to filter the RMA normalised data. The
cross gene error model (CGEM) and a parametric analysis
of variance between groups (ANOVA) statistical test was
applied and the false discovery rate was set at 0.05. 3.
ANOVA lists (2.) were further filtered to remove any gene
whose change was less than 1.4 fold were removed. The
Differentials gene lists were entered into Excel and a pivot
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table of genes was prepared and ordered according to the
number of times the genes appeared over the whole con-
dition set (see Additional file 3 Table One for lists of that
appear in at least three conditions). Differentially regu-
lated genes present in more than two conditions were vis-
ualised using Venn diagrams for each condition at each
time point. The HUGO approved names were obtained
for the University of Michigan list of apoptosis regulators
[15], combined with the lists of differentially changed
genes and a list of apoptotic genes was obtained (see
Additional file 4 Table Two for full apoptosis list). Genes
from the apoptosis list with an apoptotic pathway
recorded from the literature were mapped onto a simpli-
fied Kyoto Encyclopedia of Genes and Genomes (KEGG)/
BD Biosciences pathway [33,34].
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